Impact BioMedical Inc. (IBO) Stock Score, Valuation & Financial Research

Impact BioMedical Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IBO

Impact BioMedical Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.60. These figures are a research snapshot, not a buy or sell recommendation.

What Impact BioMedical Inc. does

Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Impact BioMedical Inc. operates by discovering, confirming, and patenting unique science and technologies. It generates revenue through licensing, co-development, joint ventures, and other collaborative relationships with external partners in the healthcare and wellness sectors, while also exploring potential direct sales for commercialization.

Products and services

  • The company focuses on the development of intellectual property and technologies in human healthcare and wellness, including assets such as Laetose, which has a unique composition patent.

Brands and product families

  • Laetose — A proprietary technology with a unique composition patent allowed in the United States. Source

Business strengths to evaluate

  • Portfolio of patented science and technologies in healthcare and wellness Source

Business risks and research considerations

  • Going concern audit opinion regarding the company's ability to continue as a going concern Source

Sources: Company research source · Laetose · Going concern audit opinion regarding the company's ability to continue as a going concern

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IBO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.60
Market capitalization:
47.84M (currency not supplied)
Revenue:
USD 35K
Net income:
USD 789K
Free cash flow:
USD -1.89M
Cash:
USD 10K
Total debt:
USD 0.00
EPS:
USD -1.23

What stands out

  • Reported year-over-year revenue growth is +9.4%.
  • Free cash flow is USD -1.89M, negative for the stored period.
  • The balance sheet shows USD 10K of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -5400.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals 2254.3% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 10K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IBO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can IBO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can IBO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IBO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IBO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research IBO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.